不要自寻烦恼:肠杆菌科和铜绿假单胞菌氟喹诺酮类折点修订
2019年CLSI基于药代动力学和药效学分析修订了肠杆菌科和铜绿假单胞菌的氟喹诺酮类药敏折点,因原折点过高且无法检测低水平耐药。本文综述支持该修订的已发表数据及对临床实验室的潜在挑战。
要点
- CLSI于2019年修订肠杆菌科和铜绿假单胞菌氟喹诺酮类折点。
- 修订依据为药代动力学和药效学分析提示原折点过高。
- 原折点无法检测低水平耐药,修订后实验室面临挑战。
核心结论
- CLSI基于药代动力学和药效学分析修订了肠杆菌科和铜绿假单胞菌的氟喹诺酮类折点,因原折点过高且无法检测低水平耐药。
研究设计与样本
- 本文为小型综述,回顾支持2019年CLSI氟喹诺酮类折点修订的已发表数据及对临床实验室的潜在挑战。
主要发现
- 药代动力学和药效学分析提示原折点过高。
- 原折点无法检测对氟喹诺酮类的低水平耐药。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Fluoroquinolones remain some of the more commonly prescribed antimicrobial agents in the United States, despite the wide array of reported side effects that are associated with their use. In 2019, the Clinical and Laboratory Standards Institute revised the fluoroquinolone antimicrobial susceptibility testing breakpoints for both Enterobacteriaceae and Pseudomonas aeruginosa This breakpoint revision was deemed necessary on the basis of pharmacokinetic and pharmacodynamic analyses suggesting that the previous breakpoints were too high, in addition to the inability of the previous breakpoints to detect low-level resistance to this antibiotic class. In this minireview, we review the published data in support of this revision, as well as the potential challenges that these breakpoint revisions are likely to pose for clinical laboratories.
引用
- Van TT, Minejima E, Chiu CA, et al. Don't Get Wound Up: Revised Fluoroquinolone Breakpoints for Enterobacteriaceae and Pseudomonas aeruginosa. J Clin Microbiol. 2019. PMID: 31043468. doi:10.1128/JCM.02072-18
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。